EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH (EEJPH)

ISSN: 2992-4081 ©EEJPH Publications

Volume 6 Issue 1 2024

Evaluating the Effectiveness of Artemisinin-Based Combination Therapy (ACT) in Reducing Malaria Recurrence Rates among Children under Five in Sub-Saharan Africa

Bizimana Rukundo T.

Faculty of Biological Sciences Kampala International University Uganda

ABSTRACT

Malaria continues to pose a significant public health threat in Sub-Saharan Africa, particularly affecting children under five who are at high risk for recurrence and associated complications. This review critically evaluates the effectiveness of Artemisinin-Based Combination Therapy (ACT) in reducing malaria recurrence rates in this vulnerable population. We explored the mechanisms of action of ACT, including the pharmacodynamics of artemisinin derivatives and their partner drugs, and assess the clinical efficacy of various ACT regimens through a synthesis of recent clinical trials and observational studies. Challenges to the implementation of ACT, such as supply chain issues, socioeconomic barriers, and healthcare workforce limitations, are discussed alongside gaps in knowledge and future research directions. We emphasize the need for ongoing resistance monitoring, optimized dosing regimens, and the integration of ACT with preventive measures to enhance treatment outcomes. Additionally, community engagement and behavioral insights are highlighted as vital components for improving adherence to treatment protocols. This review employed a comprehensive literature analysis to provide an evidence-based assessment of ACT, ultimately aiming to inform policies and future research efforts aimed at improving malaria management in young children across Sub-Saharan Africa.

Keywords: Artemisinin-Based Combination Therapy (ACT), Malaria Recurrence, Children Under Five, Sub-Saharan Africa, Efficacy and Implementation.

INTRODUCTION

Malaria remains one of the most severe public health threats in Sub-Saharan Africa, particularly affecting children under five, who bear a disproportionately high burden of disease and mortality [1, 2]. This age group is not only vulnerable due to their developing immune systems but also faces a heightened risk of recurrence, which can exacerbate malnutrition, impair cognitive development, and increase the probability of fatal outcomes. As one of the primary interventions recommended by the World Health Organization (WHO), Artemisinin-based Combination Therapy (ACT) has become the standard of care in malaria-endemic regions due to its potent efficacy against Plasmodium falciparum, the parasite responsible for the most severe cases of malaria [3]. ACT combines artemisinin derivatives with longer-acting partner drugs to enhance therapeutic efficacy and reduce the risk of parasite resistance a critical concern as resistance has already emerged in parts of Southeast Asia. Despite ACT's significant advances in malaria treatment, questions remain regarding its effectiveness in reducing malaria recurrence, particularly in high-transmission areas across Sub-Saharan Africa. Studies indicate that while ACT can rapidly clear parasites, variations in recurrence rates persist due to factors such as regional transmission intensity, drug adherence, and the pharmacokinetics of the partner drug [4, 5]. Moreover, children who experience recurrent malaria face cumulative health impacts that exacerbate the socioeconomic challenges of affected communities. This review evaluates current evidence on the efficacy of ACT in minimizing malaria recurrence among children under five, aiming to identify factors influencing outcomes and areas where intervention strategies could be optimized. By exploring the mechanisms, clinical efficacy, and implementation challenges of ACT, this review seeks to provide an evidence-based assessment that can inform policies and future

research, ultimately contributing to improved health outcomes for one of the most vulnerable populations in the global fight against malaria.

Mechanisms of Action and Pharmacodynamics of Act in Malaria Treatment

Artemisinin-based Combination Therapy (ACT) leverages the unique pharmacological properties of artemisinin derivatives combined with a partner drug to provide a robust therapeutic approach against Plasmodium falciparum [6]. Artemisinin, derived from the Artemisia annua plant, has a rapid onset of action and effectively targets the asexual blood stages of the parasite, which are responsible for the clinical manifestations of malaria [7, 8]. Its mechanism centers on the activation of artemisinin's endoperoxide bridge by heme, a byproduct of the parasite's hemoglobin digestion. This activation produces reactive oxygen species, causing extensive cellular damage within the parasite and leading to its rapid clearance from the bloodstream. Artemisinin's short half-life, however, necessitates the inclusion of a partner drug with a longer half-life to eliminate residual parasites and reduce the risk of recurrence. The partner drugs in ACT regimens, such as lumefantrine, amodiaquine, or piperaquine, serve dual roles. First, they enhance the overall efficacy of the treatment by continuing to target remaining parasites after artemisinin is cleared from the bloodstream. Second, they help mitigate the development of artemisinin resistance by ensuring the parasite population is exposed to sustained therapeutic levels of antimalarial compounds. These partner drugs have varying mechanisms of action, often interfering with parasite metabolism, nucleic acid synthesis, or membrane stability, leading to parasite death. For instance, lumefantrine inhibits the detoxification of heme within the parasite, effectively starving it of an essential growth factor. Piperaquine, on the other hand, disrupts the parasite's nucleic acid synthesis, hampering its replication. The pharmacokinetic compatibility between artemisinin and its partner drugs is crucial to the success of ACT regimens. This compatibility ensures that therapeutic drug levels persist for a sufficient period to achieve parasite clearance, especially in cases of high parasite load typical in severe malaria. The pharmacodynamic complementarity of artemisinin and its partner drug not only contributes to reducing malaria recurrence but also provides a barrier against resistance, extending the longevity and efficacy of ACT as a treatment strategy for pediatric malaria in Sub-Saharan Africa.

Clinical Efficacy of Act in Reducing Malaria Recurrence in Children Under Five

The efficacy of ACT in reducing malaria recurrence among children under five in Sub-Saharan Africa has been established through multiple clinical trials and observational studies [9]. These studies typically measure outcomes such as parasite clearance rates, duration of protection, and incidence of recurrent malaria episodes post-treatment. A pooled analysis of clinical trials in high-transmission regions reveals that ACT regimens achieve high initial efficacy rates, with parasite clearance times typically occurring within 48 hours for most patients. Such rapid clearance is critical for reducing the immediate morbidity associated with malaria infection, particularly in young children who are at risk for severe complications. Despite these encouraging initial results, recurrence rates remain a concern in areas with intense transmission. For instance, studies have noted that recurrence can occur within weeks or months following initial treatment, often due to reinfection rather than recrudescence of the original infection. Reinfection is particularly prevalent in high-transmission settings, where individuals are continually exposed to infected mosquitoes. However, ACT regimens incorporating longer-acting partner drugs, such as dihydroartemisinin-piperaquine, have demonstrated extended protective efficacy, reducing the frequency of reinfection during the post-treatment period [10, 11]. These regimens are especially beneficial for young children, who may lack the partial immunity developed by adults in endemic regions. The choice of partner drug within ACT regimens is another factor impacting recurrence rates. Studies comparing different ACT combinations, such as artemether-lumefantrine and dihydroartemisinin-piperaquine, have highlighted variations in protective duration. Regimens with longer-acting partner drugs have been shown to confer protection for up to several weeks, offering a critical advantage in high-transmission settings. However, challenges such as adherence to the full course of treatment, drug tolerability, and side effects impact the long-term efficacy of ACT in reducing malaria recurrence. Ultimately, while ACT regimens are highly effective in initial parasite clearance, their role in preventing recurrence depends on multiple factors, including transmission intensity, partner drug selection, and adherence. Continued research and tailored interventions are necessary to optimize ACT outcomes, particularly for children under five, who face unique physiological and immunological challenges that make malaria management more complex in this age group.

Challenges in the Implementation of Act for Malaria Recurrence Reduction

Implementing ACT (Artemisinin-Based Combination Therapy) across Sub-Saharan Africa, particularly among children under five, presents significant challenges. Despite being one of the most effective treatments available, logistical, socioeconomic, and cultural barriers impede the consistent and optimal use of ACT, thereby impacting its effectiveness in reducing malaria recurrence rates [12, 13].

i. **Supply Chain and Accessibility Issues:** A well-functioning supply chain is critical for the continuous availability of ACT in malaria-prone areas. However, stockouts and distribution inefficiencies are

common challenges in Sub-Saharan Africa. Factors such as poor infrastructure, limited cold storage facilities, and inadequate resources for transporting drugs to remote locations contribute to drug shortages. Moreover, resource constraints limit the reach of health facilities, often requiring families to travel great distances to access treatment. These logistical barriers result in delays in treatment initiation and the potential for incomplete dosing, which can weaken ACT's effectiveness and promote drug resistance.

ii. **Socioeconomic and Financial Barriers:** While ACT is recommended for children under five, its cost can be prohibitive for low-income families without adequate subsidies or financial support programs. Economic challenges often prevent caregivers from adhering to prescribed treatment regimens, with many opting to administer partial doses or rely on over-the-counter medications due to cost limitations. The presence of ACT subsidies in some countries has been beneficial, yet inconsistencies in subsidy coverage across regions and countries limit equitable access to treatment. Additionally, the financial prioritization of malaria interventions in healthcare budgets can impact the availability and quality of ACT distribution programs.

iii. **Awareness, Education, and Cultural Perceptions:** Lack of awareness and education regarding ACT's importance in malaria recurrence prevention also hampers its effective implementation. In some communities, caregivers may lack knowledge of the importance of completing ACT regimens, leading to non-adherence and potentially contributing to recurring infections. Cultural beliefs and traditional medicine practices may further impact treatment adherence, as individuals may be inclined to use herbal remedies instead of ACT. Consequently, health campaigns tailored to these communities are essential for improving ACT adherence and promoting early treatment-seeking behavior.

iv. **Healthcare Workforce and Capacity Limitations:** The availability of trained healthcare personnel who can accurately diagnose malaria and prescribe ACT is limited in rural and remote areas. In such contexts, the absence of qualified health workers can delay or prevent the administration of ACT in a timely manner. Moreover, training healthcare workers in ACT management protocols and educating them about potential side effects and dosage schedules are vital for reducing recurrence rates. Without addressing workforce shortages, the delivery of ACT to vulnerable populations will continue to face challenges. Addressing these multifaceted implementation issues requires concerted efforts at various levels, including improvements in healthcare infrastructure, strategic investments in rural health services, and community-focused educational programs. Overcoming these barriers will ensure that ACT achieves its full potential in reducing malaria recurrence rates among children under five in Sub-Saharan Africa.

Gaps in Knowledge and Future Research Directions for Act Efficacy

Although ACT has demonstrated effectiveness in reducing malaria recurrence rates, further research is essential to optimize its use and address emerging challenges. Identifying and closing these knowledge gaps is critical for enhancing ACT's long-term efficacy in Sub-Saharan Africa, particularly for vulnerable groups such as children under five [14].

i. **Resistance Development and Drug Efficacy Monitoring:** Artemisinin resistance poses one of the most significant threats to ACT's future efficacy. Studies have documented cases of resistance emerging in certain parts of Africa, highlighting an urgent need for surveillance systems that can detect early resistance patterns. Future research should focus on tracking resistance markers and monitoring ACT's clinical efficacy over time. Additionally, exploring combination therapies with alternative antimalarial agents may offer insights into sustaining ACT's potency, especially in high-burden regions.

ii. **Understanding the Influence of Environmental and Genetic Factors:** Variations in environmental conditions, such as climate and seasonal changes, affect malaria transmission rates, which may influence ACT's effectiveness [1, 15]. More research is needed to understand how these factors impact malaria recurrence and how treatment protocols can be adjusted based on seasonality or local environmental patterns. Genetic factors, both within the parasite population and among human hosts, also play a role in treatment efficacy. For instance, certain genetic mutations in *Plasmodium falciparum* can confer resistance, while human genetic traits such as G6PD deficiency may impact ACT tolerance and effectiveness.

iii. **Optimal Dosing Regimens and Age-Specific Adjustments:** Current ACT dosing guidelines may not adequately consider age-specific metabolic rates and immune responses among children under five. Research into optimized dosing protocols that account for age, weight, and other biological factors is necessary for refining ACT efficacy and safety. Additionally, studies examining the pharmacokinetics of artemisinin and partner drugs in young children can yield insights into more effective dosing schedules, potentially reducing recurrence rates by ensuring consistent therapeutic levels.

iv. **Integrating ACT with Preventive Measures:** Research on the synergistic effects of ACT in combination with preventive measures, such as insecticide-treated bed nets, seasonal malaria chemoprevention, and vaccination, is limited. By exploring how ACT interacts with these interventions, studies can provide a clearer understanding of comprehensive malaria control strategies. Evidence on how preventive measures can be tailored alongside ACT administration to maximize recurrence reduction, especially in high-transmission settings, would be valuable for formulating integrated approaches to malaria management.

v. **Community Engagement and Behavioral Insights:** Community adherence to ACT treatment regimens remains a challenge in malaria-endemic areas. Behavioral studies are needed to explore factors that influence adherence, including social, cultural, and psychological aspects. Research should investigate community-based interventions and educational initiatives that foster greater understanding and acceptance of ACT, focusing on addressing misconceptions and reducing treatment barriers. Additionally, investigating caregiver perceptions of malaria recurrence and ACT's role could guide more effective educational campaigns, improving adherence and reducing relapse rates. By addressing these critical research gaps, the healthcare community can work toward refining ACT protocols, enhancing treatment adherence, and mitigating the risk of malaria recurrence among young children. Future studies should prioritize a multi-disciplinary approach, encompassing pharmacological research, behavioral studies, and community engagement to develop robust, sustainable malaria treatment strategies tailored to the unique needs of Sub-Saharan Africa's pediatric population.

CONCLUSION

Artemisinin-based Combination Therapy (ACT) has proven to be a cornerstone in the fight against malaria, particularly in reducing recurrence rates among children under five in Sub-Saharan Africa. Its rapid action against Plasmodium falciparum, combined with the long-lasting effects of partner drugs, has significantly improved initial treatment outcomes. However, the persistence of malaria recurrence highlights the need for a more nuanced understanding of the various factors influencing ACT's efficacy. Challenges related to implementation, including supply chain inefficiencies, socioeconomic barriers, and cultural perceptions, continue to hinder optimal treatment outcomes. Future research is essential to address the emerging challenges of resistance, optimize dosing regimens, and integrate ACT with preventive strategies to enhance its effectiveness. A multi-disciplinary approach that includes monitoring resistance patterns, understanding environmental and genetic influences, and fostering community engagement will be crucial in tailoring interventions to the unique needs of pediatric populations. As the global health community seeks to eliminate malaria, continuous efforts to optimize ACT utilization and address the gaps in knowledge will be critical. By improving adherence to treatment protocols, enhancing access to ACT, and fostering community awareness, we can significantly mitigate the impact of malaria on vulnerable children in Sub-Saharan Africa. Ultimately, a concerted focus on these areas will contribute to better health outcomes and a reduction in the socioeconomic burden of malaria in the region, paving the way for a future free from the devastation of this preventable disease.

REFERENCES

1. Alum, E., Ugwu, P.-C., Simeon, E., Uti, D., Alum, B.N.: Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. INOSR Scientific Research. 11, 16–22 (2024). https://doi.org/10.59298/INOSRSR/2024/1.1.21622
2. Stonely, A.: Prevalence of Malaria in Sub-Saharan Africa. Ballard Brief. 2023, (2023)
3. Alven, S., Aderibigbe, B.: Combination Therapy Strategies for the Treatment of Malaria. Molecules. 24, 3601 (2019). https://doi.org/10.3390/molecules24193601
4. Wijnant, G.-J., Dumetz, F., Dirkx, L., Bulté, D., Cuypers, B., Van Bocxlaer, K., Hendrickx, S.: Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis. Front. Trop. Dis. 3, (2022). https://doi.org/10.3389/fitd.2022.837460
5. Ferraz, L.R.M., Silva, L.C.P.B.B., Souza, M.L. de, Alves, L.P., Sales, V. de A.W., Barbosa, I. do N.G., Andrade, M.C. de, Santos, W.M. dos, Rolim, L.A., Rolim-Neto, P.J.: Drug associations as alternative and complementary therapy for neglected tropical diseases. Acta Tropica. 225, 106210 (2022). https://doi.org/10.1016/j.actatropica.2021.106210
6. Ansbro, M. R., Itkin, Z., Chen, L., Zahoranszky-Kohalmi, G., Amaratunga, C., Miotto, O., & Eastman, R. T. (2020). Modulation of triple artemisinin-based combination therapy pharmacodynamics by plasmodium falciparum genotype. *ACS pharmacology & translational science*, *3*(6), 1144-1157.
7. Rai, S.K., Apoorva, Rai, K.K., Pandey-Rai, S.: New perspectives of the *Artemisia annua* bioactive compounds as an affordable cure in treatment of malaria and cancer. In: Sinha, R. p. and Häder, D.-P. (eds.) Natural Bioactive Compounds. pp. 299–315. Academic Press (2021)
8. Erisa, K., Raphael, I., P.C., U., Alum, E.: Exploration of Medicinal Plants Used in the Management of Malaria in Uganda. (2023)

9. Mavoko, H.M., Nabasumba, C., Luz, R.I. da, Tinto, H., D'Alessandro, U., Kambugu, A., Baraka, V., Rosanas-Urgell, A., Lutumba, P., Geertruyden, J.-P.V.: Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. The Lancet Global Health. *5*, e60–e68 (2017). https://doi.org/10.1016/S2214-109X(16)30236-4
10. Goodwin, J. (2024). *Malaria Parasite, Host, and Drug Dynamics in the Context of Artemether-Lumefantrine Treatment and HIV-Infection* (Doctoral dissertation, Yale University).
11. Mbah, M.L.N., Parikh, S., Galvani, A.P.: Comparing the Impact of Artemisinin-Based Combination Therapies on Malaria Transmission in Sub-Saharan Africa. The American Journal of Tropical Medicine and Hygiene. *92*, 555 (2015). https://doi.org/10.4269/ajtmh.14-0490
12. Bawate, C., Callender-Carter, S.T., Guyah, B., Ouma, C.: Factors influencing patients' adherence to malaria Artemisinin-based combination therapy treatment in Kamuli District, Uganda, https://www.researchsquare.com/article/rs-3402147/v1, (2023)
13. Githinji, B.: Preventing Malaria in Western Kenya through Educational Interventions and Treatment Combination of Indoor Residual Spraying with Insecticide Treated Mosquito Nets: An Integrated Review. Doctoral Dissertations and Projects. (2021)
14. Oladipo, H. J., Tajudeen, Y. A., Oladunjoye, I. O., Yusuff, S. I., Yusuf, R. O., Oluwaseyi, E. M., ... & El-Sherbini, M. S. (2022). Increasing challenges of malaria control in sub-Saharan Africa: Priorities for public health research and policymakers. *Annals of Medicine and Surgery*, *81*, 104366.
15. Ssempiira, J., Kissa, J., Nambuusi, B., Mukooyo, E., Opigo, J., Makumbi, F., Kasasa, S., Vounatsou, P.: Interactions between climatic changes and intervention effects on malaria spatio-temporal dynamics in Uganda. Parasite Epidemiology and Control. *3*, e00070 (2018). https://doi.org/10.1016/j.parepi.2018.e00070

CITE AS: Bizimana Rukundo T. (2024). Evaluating the Effectiveness of Artemisinin-Based Combination Therapy (ACT) in Reducing Malaria Recurrence Rates among Children under Five in Sub-Saharan Africa. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 6(1):21-25.